Form 4: Teva Director Ronit Satchi-Fainaro Reports Share Transactions

Teva Pharmaceutical Industries Ltd. Director Ronit Satchi-Fainaro has reported transactions involving ordinary shares and restricted share units.

Summary

• Ronit Satchi-Fainaro, a Director at Teva Pharmaceutical Industries Ltd., reported a transaction on June 5, 2026.
• The transaction involved the acquisition of 14,492 ordinary shares.
• Following this transaction, Satchi-Fainaro beneficially owns 112,401 ordinary shares.
• Restricted share units granted on June 5, 2025, vested on June 5, 2026, resulting in the acquisition of 14,492 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions related to share awards and does not indicate significant new strategic information or financial performance.

Positives

• Director Ronit Satchi-Fainaro acquired 14,492 ordinary shares, indicating continued investment or alignment with the company.
• The vesting of restricted share units suggests that performance or tenure-based incentives were met.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to insider transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical industry, providing transparency on executive and director holdings.

Stakeholder Impact

• Shareholders: Increased transparency regarding director's beneficial ownership and potential alignment of interests.

Key Dates

Keywords

Teva Pharmaceutical Industries, Form 4, Insider Trading, Beneficial Ownership, Director Transaction, Ordinary Shares, Restricted Share Units